

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Director/PDMR Shareholding

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 18 and 19 October 2017 it purchased 256,520 and 193,100 ordinary shares of 1p each, respectively, in the capital of the Company ("Ordinary Shares") at an average price of 3.075p per Ordinary Share (the "Purchase") and on 20 October it purchased 119,636 ordinary shares of 1p each at a price of 3.15p per Ordinary Share. Following the Purchase, Vulpes has a total direct and indirect interest in 55,012,971 equivalent to 18.64% of Proteome Sciences' total issued share capital.

The Company would also like to announce that by virtue of Martin Diggle being a Director of both Vulpes and the Company, he now has an interest in 55,012,971 Ordinary Shares of the Company representing 18.64% of the issued share capital of the Company.

1. Details of the person discharging managerial responsibilities / person closely associated
 - a) Name Vulpes Life Sciences Fund
2. Reason for the Notification
 - a) Position/status PCA of Martin Diggle (NED)
 - b) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name Proteome Sciences plc
 - b) LEI n/a
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
 - a) Description of the Financial instrument, type of instrument Ordinary Shares of 1p each
Identification code GB0003104196
 - b) Nature of the transaction Purchase
 - c) Price(s) and volume(s) 256,520 Ordinary Shares at 3p per Ordinary Share

193,100 Ordinary Shares at 3.15p per Ordinary Share

119,636 Ordinary Shares at 3.15p per Ordinary Share
- d) Aggregated information:
 - Aggregated volume 569,256 Ordinary Shares of 1p each purchased at an average price of 3.1125p per Ordinary Share
 - Price
- e) Date of the transaction 18, 19 & 20 October 2017
- f) Place of the transaction London Stock Exchange, AIM Market (XLON)

For further information:

Proteome Sciences plc

Jeremy Haigh, Chief Executive Officer

Tel: +44 (0)20 7043 2116

Ian Pike, Chief Scientific Officer

Stefan Fuhrman, Interim Finance Director

finnCap Limited (Nominated Adviser/Broker)

Geoff Nash/James Thompson

Tel: +44 (0)20 7220 0500

Tony Quirke (broking)

IFC Advisory (Financial PR and IR)

Tim Metcalfe/Graham Herring/Miles Nolan

Tel: +44 (0)20 3053 8671

Notes for editors:

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant[®]) and for the discovery, validation and assay development of protein biomarkers (TMTcalibrator[™]). The company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services[™] division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.

Proteome Sciences has patented a number of novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.